What is Laboratorios Farmaceuticos Rovi Cash Ratio?
Laboratorios Farmaceuticos RoviLABFF 93 Cash Ratio is 0.66 as of Mar. 2026, which is 32% above its 10-year median of 0.50. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 975 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 51.9% on this metric.
Laboratorios Farmaceuticos Rovi has a Cash Ratio of 0.66. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Cash Ratio or its related term are showing as below:
LABFF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.07 Med: 0.5 Max: 1.09
Current: 0.66
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Cash Ratio was 1.09. The lowest was 0.07. And the median was 0.50.
LABFF's Cash Ratio is ranked better than 51.9% of 975
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs LABFF: 0.66
Laboratorios Farmaceuticos Rovi (OTCPK:LABFF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Laboratorios Farmaceuticos Rovi Cash Ratio Related Terms
Laboratorios Farmaceuticos Rovi Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a Cash Ratio of 0.66 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 32% above median its historical median of 0.50. Over the past decade, Laboratorios Farmaceuticos Rovi's Cash Ratio has ranged from 0.07 to 1.09. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #469 out of 975 companies in the Drug Manufacturers industry, placing it in the top 48.1%.
Is Laboratorios Farmaceuticos Rovi's Cash Ratio too high?
Laboratorios Farmaceuticos Rovi's current Cash Ratio of 0.66 is 32% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 1.09. The Drug Manufacturers industry median Cash Ratio is 0.61. Laboratorios Farmaceuticos Rovi's value of 0.66 is 8.2% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #469 out of 975 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #469 out of 975 companies for Cash Ratio. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Cash Ratio is 0.61. Laboratorios Farmaceuticos Rovi's value of 0.66 is 8.2% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Cash Ratio has ranged from 0.07 to 1.09 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.61, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Cash Ratio of 0.66 is 8.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Cash Ratio is 0.66, which is 32% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Cash Ratio of 0.66. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Cash Ratio is 0.66, which is 32% above median its 10-year median of 0.50 and 8.2% above the Drug Manufacturers industry median of 0.61. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Cash Ratio is 0.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Cash Ratio: 0.66 (32% above median its 10-year median of 0.50)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 8.2% above the Drug Manufacturers median (#469 of 975)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
